Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen- induced bronchoconstriction in patients with asthma

Chest

Volumn 114, Issue 4, 1998, Pages 1028-1032

  Obase, Yasushi ^a   Shimoda, Terufumi ^a   Matsuo, Nobuko ^a   Matsuse, Hiroto ^a   Asai, Sadahiro ^b   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Sasebo Shiritsu Sogo Hospital   (Japan)

Author keywords

Antigen induced bronchoconstriction; Chemical mediators; Cysteinyl leukotriene receptor antagonist; Thromboxane A2 receptor antagonist; Thromboxane A2 synthetase inhibitor

Indexed keywords

11 OXOTHROMBOXANE B2; BECLOMETASONE DIPROPIONATE; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE; HOUSE DUST ALLERGEN; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OZAGREL; PEPTIDOLEUKOTRIENE; PRANLUKAST; SERATRODAST; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR;

ADULT; ALLERGIC ASTHMA; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION TEST; INHALATIONAL DRUG ADMINISTRATION; MALE; MEDIATOR RELEASE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0031732417     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.114.4.1028     Document Type: Article

References (20)

1. National Heart, Lung, and Blood Institute and World Health Organization. Global initiative for asthma. NIH publication no. 95-3659. Bethesda, MD: National Institutes of Health, 1995; 47-61
2. Dahlen S-E, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288:484-486
3. 4 increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126:449-451
4. Woodward DF, Weichman BM, Gill CA, et al. The effect of synthetic Icukotrienes on tracheal microvascular permeability. Prostaglandins 1983; 25:131
5. 2: effects on airway and vascular smooth muscle. Prostaglandins 1977; 14:425-436
6. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA, 1975; 72:2994
7. 2, and prostacyclin. Pharmacol Rev 1979; 30:293
8. 2. Fed Proc 1987; 46:133-138
9. 2 formation (1). N Engl J Med 1988; 319:689-698
10. Taniguchi Y, Tamura G, Homma M, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92:507-512
11. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337:690-694
12. Chai H, Farr RS, Forchlich LA, et al. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975; 56:323-327
13. 2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis 1990; 142:126-132
14. 4 in humans: effect of indomethacin. Am Rev Respir Dis 1990; 141:1441-1445
15. Larsen GL. The pulmonary late-phase response. Hosp Pract (Off Ed) 1987; 22:155-159, 163, 167-169
16. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111:27S-34S
17. Findlay SR, Barden JM, Easley CB, et al. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89:1040-1045
18. Manning PJ, Stevens WH, Cockcroft DW, et al. The role of thromboxane in allergen-induced asthmatic responses. Eur Respir J 1991; 4:667-672
19. Matsumoto T, Ashida Y, Tsukuda R. Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig. J Pharmacol Exp Ther 1994; 269:1236-1244
20. 4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146:96-103